IQVIA™ Real-World Insights Bibliography
Assessment of the economic value of the INTERCEPT Blood System in Belgium. |
Author(s): Moeremans K; Annemans L. |
Affiliations(s): |
Publication(s): Transfusion Medicine, 2006; 16:17-30
|
Document Type(s): Manuscript in preparation, |
Countries: Belgium, |
C: Y: |
Health economics, 2006 |
|
L: A: |
English
|
|
|
|
|
Assesment of the economic value of the INTERCEPT blood system in Belgium. |
Author(s): Moeremans K, Warie H, Annemans L |
Affiliations(s): |
Publication(s): Transfus Med.; 16:17-30
|
Document Type(s): Manuscript in preparation, |
Countries: Belgium, |
C: Y: |
Hematology, 2006 |
|
L: A: |
English
|
|
|
|
|
A cost-consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (WQ_EB) in patients with chemotherapy-induced anemia (CIA): A retrospective study. |
Author(s): Van Bellinghen LA, Demarteau N, Annemans, Bracco A |
Affiliations(s): |
Publication(s): ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark
|
Document Type(s): Poster, |
Countries: Belgium, |
C: Y: |
Oncology, 2006 |
|
L: A: |
English Cost consequence, |
|
|
|
|
An update: Health economics of managing multiple myeloma |
Author(s): K Moeremans, L Annemans. |
Affiliations(s): |
Publication(s): European Journal of Cancer, 2006; 42(11):1684-96
|
Document Type(s): Manuscript in preparation, |
Countries: Belgium, |
C: Y: |
Oncology, 2006 |
|
L: A: |
English
|
|
|
|
|
Treatment of actinic keratosis (AK) and basal cell carcinoma (BCC) with Metvix® (MAL-PDT) in real life practice: a cost of illness and model validation study. |
Author(s): Caekelbergh K1, Annemans L1 |
Affiliations(s): 1 IMS Health, Brussels, Belgium |
Publication(s): ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark
|
Document Type(s): Poster, |
Countries: Belgium, |
C: Y: |
Oncology, 2006 |
|
L: A: |
English Cost of illness, |
|
|
|
|
15 of 15
|
|